Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1190 participants
OBSERVATIONAL
2013-12-31
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnostic Value of KL-6 in ILD
NCT03103191
Sequential Changes of Serum KL-6 Predict Progression in Interstitial Lung Disease
NCT02960672
Autologous Lung Stem Cell Transplantation in Patients With Interstitial Lung Diseases
NCT02796781
Serum Interleukin 6 in Chronic Obstructive Pulmonary Disease
NCT05214508
Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)
NCT02827734
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Part 1: The purpose of this part is to evaluate the role of KL-6 as a biomarker in the clinical diagnosis of interstitial lung disease (ILD) by detecting serum KL-6 levels among patients with ILD, and comparing them to the clinical diagnostic criteria and other respiratory diseases, including pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease and healthy control group.
Part 2: The purpose of this part is to study the value of KL-6 levels in terms of ILD treatment effect evaluation through the detection of serum KL-6 levels before treatment and 30-90 days after treatment. Treatment includes anti fibrosis, anti-inflammatory and other conventional therapies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ILD, Other respiratory diseases, Healthy control group
ILD: those with interstitial lung disease.
Other respiratory diseases: those with other respiratory disease including pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease.
Healthy control group: those who is healthy.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Serums from patients with ILD: before treatment and 30-90 days after treatment
Exclusion Criteria
* Serums with visible precipitate
* Serums with floc
14 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fujirebio Diagnostics, Inc.
INDUSTRY
Shanghai Pulmonary Hospital, Shanghai, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Huiping Li
Professor,Chief of Dept. of Respiratory Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Li Hui Ping
Role: PRINCIPAL_INVESTIGATOR
Shanghai Pulmonary Hospital , Tongji University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KL-6_20140715
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.